Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Non-Current Deferred Tax Liability: 2019-2021

Historic Non-Current Deferred Tax Liability for Legend Biotech (LEGN) over the last 3 years, with Dec 2021 value amounting to $22.8 million.

  • Legend Biotech's Non-Current Deferred Tax Liability fell 35.05% to $22.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was $22.8 million, marking a year-over-year decrease of 35.05%. This contributed to the annual value of $22.8 million for FY2021, which is 35.05% down from last year.
  • Latest data reveals that Legend Biotech reported Non-Current Deferred Tax Liability of $22.8 million as of FY2021, which was down 35.05% from $35.0 million recorded in FY2020.
  • In the past 5 years, Legend Biotech's Non-Current Deferred Tax Liability registered a high of $47.7 million during FY2019, and its lowest value of $22.8 million during FY2021.
  • For the 3-year period, Legend Biotech's Non-Current Deferred Tax Liability averaged around $35.2 million, with its median value being $35.0 million (2020).
  • Data for Legend Biotech's Non-Current Deferred Tax Liability shows a maximum YoY plummeted of 35.05% (in 2021) over the last 5 years.
  • Legend Biotech's Non-Current Deferred Tax Liability (Yearly) stood at $47.7 million in 2019, then fell by 26.54% to $35.0 million in 2020, then slumped by 35.05% to $22.8 million in 2021.